Contemporary trends in cardiac electrophysiology procedures in the United States, and impact of a global pandemic

[1]  A. Verma,et al.  Progression of Atrial Fibrillation after Cryoablation or Drug Therapy. , 2022, The New England journal of medicine.

[2]  T. Bunch,et al.  Impact of early ventricular tachycardia ablation in patients with an implantable cardioverter defibrillator: An updated systematic review and meta-analysis of randomized control trials. , 2022, Heart rhythm.

[3]  B. Nazer,et al.  Temporal and geographical trends in women operators of electrophysiology procedures in the United States. , 2022, Heart rhythm.

[4]  P. Santangeli,et al.  Electrophysiology and Interventional Cardiology Procedure Volumes During the Coronavirus Disease 2019 Pandemic , 2021, Cardiac Electrophysiology Clinics.

[5]  C. Morillo,et al.  Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation. , 2020, The New England journal of medicine.

[6]  R. Jackson,et al.  Ten‐year trends in cardiac implantable electronic devices in New Zealand: a national data linkage study (ANZACS‐QI 51) , 2020, Internal medicine journal.

[7]  G. Breithardt,et al.  Early Rhythm-Control Therapy in Patients with Atrial Fibrillation. , 2020, The New England journal of medicine.

[8]  Z. Kalarus,et al.  Temporal trends in availability and efficacy of catheter ablation for atrial fibrillation and atrial flutter in a highly populated urban area. , 2020, Kardiologia polska.

[9]  I. Ranasinghe,et al.  Association of Physician Specialty With Long-Term Implantable Cardioverter-Defibrillator Complication and Reoperations Rates. , 2019, Circulation. Cardiovascular quality and outcomes.

[10]  Seil Oh,et al.  Temporal Trends of Cardiac Implantable Electronic Device Implantations: a Nationwide Population-based Study , 2019, Korean circulation journal.

[11]  K. Anstrom,et al.  Effect of Catheter Ablation vs Medical Therapy on Quality of Life Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial , 2019, JAMA.

[12]  B. Gersh,et al.  Sudden death mechanisms in nonischemic cardiomyopathies: Insights gleaned from clinical implantable cardioverter-defibrillator trials. , 2017, Heart rhythm.

[13]  Hans Eiskjær,et al.  Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure. , 2016, The New England journal of medicine.

[14]  John L Sapp,et al.  Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs. , 2016, The New England journal of medicine.

[15]  Dhanunjaya R. Lakkireddy,et al.  Freedom from recurrent ventricular tachycardia after catheter ablation is associated with improved survival in patients with structural heart disease: An International VT Ablation Center Collaborative Group study. , 2015, Heart rhythm.

[16]  J. Hartikainen,et al.  Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation. , 2012, The New England journal of medicine.

[17]  Stephan Willems,et al.  Catheter ablation of stable ventricular tachycardia before defibrillator implantation in patients with coronary heart disease (VTACH): a multicentre randomised controlled trial , 2010, The Lancet.

[18]  Margaret C Fang,et al.  Trends in catheter ablation for atrial fibrillation in the United States. , 2009, Journal of hospital medicine.

[19]  D. Singer,et al.  Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. , 2001, JAMA.

[20]  J. Camm,et al.  The impairment of health-related quality of life in patients with intermittent atrial fibrillation: implications for the assessment of investigational therapy. , 2000, Journal of the American College of Cardiology.